#begin document (ectb_1029_3); part 000
ectb_1029	3	0	Where	WRB	(TOP(SBAR(WHADVP*)	-	-	-	-	-
ectb_1029	3	1	the	DT	(S(NP*	-	-	-	-	-
ectb_1029	3	2	real	JJ	*	-	-	-	-	-
ectb_1029	3	3	money	NN	*)	money	-	2	-	-
ectb_1029	3	4	is	VBZ	(VP*))))	be	01	4	-	-

ectb_1029	3	0	At	IN	(TOP(S(PP*	-	-	-	-	-
ectb_1029	3	1	present	NN	(NP*))	present	-	1	-	-
ectb_1029	3	2	,	,	*	-	-	-	-	-
ectb_1029	3	3	most	JJS	(NP(NP*	-	-	-	-	-
ectb_1029	3	4	applications	NNS	*)	-	-	-	-	-
ectb_1029	3	5	for	IN	(PP*	-	-	-	-	-
ectb_1029	3	6	biochips	NNS	(NP*)))	-	-	-	-	(35)
ectb_1029	3	7	are	VBP	(VP*	be	01	4	-	-
ectb_1029	3	8	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	9	academic	JJ	(NP(NP*	-	-	-	-	-
ectb_1029	3	10	research	NN	*)	research	-	1	-	-
ectb_1029	3	11	and	CC	*	-	-	-	-	-
ectb_1029	3	12	the	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	13	development	NN	*)	-	-	-	-	-
ectb_1029	3	14	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	15	new	JJ	(NP*	-	-	-	-	-
ectb_1029	3	16	pharmaceutical	JJ	*	-	-	-	-	-
ectb_1029	3	17	drugs	NNS	*))))))	-	-	-	-	-
ectb_1029	3	18	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Demand	NN	(TOP(S(NP(NP*)	demand	-	3	-	-
ectb_1029	3	1	for	IN	(PP*	-	-	-	-	-
ectb_1029	3	2	them	PRP	(NP*)))	-	-	-	-	(35)
ectb_1029	3	3	is	VBZ	(VP*	be	03	-	-	-
ectb_1029	3	4	growing	VBG	(VP*	grow	01	4	-	-
ectb_1029	3	5	rapidly	RB	(ADVP*)))	-	-	-	-	-
ectb_1029	3	6	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Johnsee	NNP	(TOP(S(NP*	-	-	-	-	-
ectb_1029	3	1	Lee	NNP	*)	-	-	-	-	-
ectb_1029	3	2	says	VBZ	(VP*	say	01	1	-	-
ectb_1029	3	3	that	IN	(SBAR*	-	-	-	-	-
ectb_1029	3	4	according	VBG	(S(PP*	accord	01	-	-	-
ectb_1029	3	5	to	IN	(PP*	-	-	-	-	-
ectb_1029	3	6	US	NNP	(NP*	-	-	-	-	-
ectb_1029	3	7	market	NN	(NML*	-	-	-	-	-
ectb_1029	3	8	research	NN	*)	-	-	-	-	-
ectb_1029	3	9	estimates	NNS	*)))	estimate	-	3	-	-
ectb_1029	3	10	,	,	*	-	-	-	-	-
ectb_1029	3	11	the	DT	(S(NP(NP*	-	-	-	-	(9
ectb_1029	3	12	worldwide	JJ	*	-	-	-	-	-
ectb_1029	3	13	annual	JJ	*	-	-	-	-	-
ectb_1029	3	14	consumption	NN	*)	consumption	01	1	-	-
ectb_1029	3	15	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	16	microarray	NN	(NP*	-	-	-	-	-
ectb_1029	3	17	chips	NNS	*)))	chip	-	11	-	9)
ectb_1029	3	18	is	VBZ	(VP*	be	01	1	-	-
ectb_1029	3	19	currently	RB	(ADVP*)	-	-	-	-	-
ectb_1029	3	20	around	RB	(NP(QP*	-	-	-	-	-
ectb_1029	3	21	250,000	CD	*))))	-	-	-	-	-
ectb_1029	3	22	;	,	*	-	-	-	-	-
ectb_1029	3	23	in	IN	(S(PP*	-	-	-	-	-
ectb_1029	3	24	two	CD	(NP*	-	-	-	-	-
ectb_1029	3	25	years	NNS	*))	-	-	-	-	-
ectb_1029	3	26	this	DT	(NP*)	-	-	-	-	(9)
ectb_1029	3	27	is	VBZ	(VP*	be	03	-	-	-
ectb_1029	3	28	expected	VBN	(VP*	expect	01	-	-	-
ectb_1029	3	29	to	TO	(S(VP*	-	-	-	-	-
ectb_1029	3	30	grow	VB	(VP*	grow	01	4	-	-
ectb_1029	3	31	to	IN	(PP*	-	-	-	-	-
ectb_1029	3	32	1.2	CD	(NP(QP*	-	-	-	-	-
ectb_1029	3	33	million	CD	*))))))))))))	-	-	-	-	-
ectb_1029	3	34	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Based	VBN	(TOP(S(PP*	base	02	-	-	-
ectb_1029	3	1	on	IN	(PP*	-	-	-	-	-
ectb_1029	3	2	a	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	3	market	NN	*	-	-	-	-	-
ectb_1029	3	4	price	NN	*)	-	-	-	-	-
ectb_1029	3	5	per	IN	(PP*	-	-	-	-	-
ectb_1029	3	6	chip	NN	(NP*))	chip	-	11	-	-
ectb_1029	3	7	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	8	US$	$	(NP(QP*	-	-	-	-	-
ectb_1029	3	9	1,000	CD	*))))))	-	-	-	-	-
ectb_1029	3	10	,	,	*	-	-	-	-	-
ectb_1029	3	11	the	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	12	size	NN	*)	size	-	1	-	-
ectb_1029	3	13	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	14	the	DT	(NP*	-	-	-	-	-
ectb_1029	3	15	world	NN	*	-	-	-	-	-
ectb_1029	3	16	market	NN	*))	-	-	-	-	-
ectb_1029	3	17	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	18	biochips	NNS	(NP*)))	-	-	-	-	-
ectb_1029	3	19	could	MD	(VP*	-	-	-	-	-
ectb_1029	3	20	grow	VB	(VP*	grow	01	4	-	-
ectb_1029	3	21	to	IN	(PP(PP*	-	-	-	-	-
ectb_1029	3	22	US$	$	(NP(NP(QP*	-	-	-	-	-
ectb_1029	3	23	1.2	CD	*	-	-	-	-	-
ectb_1029	3	24	billion	CD	*))	-	-	-	-	-
ectb_1029	3	25	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	26	2003	CD	(NP*))))	-	-	-	-	-
ectb_1029	3	27	,	,	*	-	-	-	-	-
ectb_1029	3	28	and	CC	*	-	-	-	-	-
ectb_1029	3	29	to	IN	(PP*	-	-	-	-	-
ectb_1029	3	30	US$	$	(NP(NP(QP*	-	-	-	-	-
ectb_1029	3	31	40	CD	*	-	-	-	-	-
ectb_1029	3	32	billion	CD	*))	-	-	-	-	-
ectb_1029	3	33	over	IN	(PP*	-	-	-	-	-
ectb_1029	3	34	the	DT	(NP*	-	-	-	-	-
ectb_1029	3	35	next	JJ	*	-	-	-	-	-
ectb_1029	3	36	decade	NN	*)))))))	decade	-	1	-	-
ectb_1029	3	37	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Thus	RB	(TOP(S(ADVP*)	-	-	-	-	-
ectb_1029	3	1	some	DT	(NP*	-	-	-	-	(36
ectb_1029	3	2	people	NNS	*)	people	-	1	-	36)
ectb_1029	3	3	have	VBP	(VP(VP*	have	01	-	-	-
ectb_1029	3	4	set	VBN	(VP*	set	01	1	-	-
ectb_1029	3	5	their	PRP$	(NP*	-	-	-	-	(36)
ectb_1029	3	6	sights	NNS	*)	-	-	-	-	-
ectb_1029	3	7	on	IN	(PP*	-	-	-	-	-
ectb_1029	3	8	the	DT	(NP*	-	-	-	-	-
ectb_1029	3	9	biochip	NN	*	-	-	-	-	-
ectb_1029	3	10	market	NN	*))))	market	-	1	-	-
ectb_1029	3	11	,	,	*	-	-	-	-	-
ectb_1029	3	12	and	CC	*	-	-	-	-	-
ectb_1029	3	13	believe	VBP	(VP*	believe	01	1	-	-
ectb_1029	3	14	that	IN	(SBAR*	-	-	-	-	-
ectb_1029	3	15	following	VBG	(S(PP*	-	-	-	-	-
ectb_1029	3	16	Taiwan	NNP	(NP(NP(NP*	-	-	-	-	(24
ectb_1029	3	17	's	POS	*)	-	-	-	-	24)
ectb_1029	3	18	success	NN	*)	success	01	2	-	-
ectb_1029	3	19	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	20	the	DT	(NP*	-	-	-	-	-
ectb_1029	3	21	semiconductor	NN	*	-	-	-	-	-
ectb_1029	3	22	field	NN	*))))	field	-	3	-	-
ectb_1029	3	23	,	,	*	-	-	-	-	-
ectb_1029	3	24	the	DT	(NP*	-	-	-	-	(24
ectb_1029	3	25	island	NN	*)	-	-	-	-	24)
ectb_1029	3	26	could	MD	(VP*	-	-	-	-	-
ectb_1029	3	27	go	VB	(VP*	go	15	1	-	-
ectb_1029	3	28	on	RB	(ADVP*)	-	-	-	-	-
ectb_1029	3	29	to	TO	(S(VP*	-	-	-	-	-
ectb_1029	3	30	be	VB	(VP*	be	01	1	-	-
ectb_1029	3	31	a	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	32	major	JJ	*	-	-	-	-	-
ectb_1029	3	33	center	NN	*)	center	-	2	-	-
ectb_1029	3	34	for	IN	(PP*	-	-	-	-	-
ectb_1029	3	35	contract	NN	(NP(NP*	contract	-	1	-	-
ectb_1029	3	36	manufacture	NN	*)	manufacture	-	1	-	-
ectb_1029	3	37	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	38	biochips	NNS	(NP*))))))))))))))	-	-	-	-	-
ectb_1029	3	39	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Be	VB	(TOP(S(SBAR(SINV*	be	01	1	-	-
ectb_1029	3	1	that	DT	(NP*)	-	-	-	-	-
ectb_1029	3	2	as	IN	(SBAR*	-	-	-	-	-
ectb_1029	3	3	it	PRP	(S(NP*)	-	-	-	-	-
ectb_1029	3	4	may	MD	(VP*)))))	-	-	-	-	-
ectb_1029	3	5	,	,	*	-	-	-	-	-
ectb_1029	3	6	the	DT	(NP(NP*	-	-	-	-	(11
ectb_1029	3	7	small	JJ	*	-	-	-	-	-
ectb_1029	3	8	number	NN	*)	number	-	1	-	-
ectb_1029	3	9	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	10	biochip	NN	(NP(NP*	-	-	-	-	-
ectb_1029	3	11	companies	NNS	*)	company	-	1	-	-
ectb_1029	3	12	so	RB	(VP(ADVP*	-	-	-	-	-
ectb_1029	3	13	far	RB	*)	-	-	-	-	-
ectb_1029	3	14	established	VBN	*	establish	01	-	-	-
ectb_1029	3	15	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	16	Taiwan	NNP	(NP*))))))	-	-	-	-	(24)|11)
ectb_1029	3	17	still	RB	(ADVP*)	-	-	-	-	-
ectb_1029	3	18	find	VBP	(VP*	find	02	1	-	-
ectb_1029	3	19	their	PRP$	(NP*	-	-	-	-	(11)
ectb_1029	3	20	market	NN	*)	market	-	1	-	-
ectb_1029	3	21	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	22	domestic	JJ	(NP(NP*	-	-	-	-	-
ectb_1029	3	23	research	NN	*	-	-	-	-	-
ectb_1029	3	24	establishments	NNS	*)	establishment	-	2	-	-
ectb_1029	3	25	and	CC	*	-	-	-	-	-
ectb_1029	3	26	pharmaceuticals	NNS	(NP*	-	-	-	-	-
ectb_1029	3	27	manufacturers	NNS	*))))	manufacturer	-	1	-	-
ectb_1029	3	28	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Although	IN	(TOP(S(SBAR*	-	-	-	-	-
ectb_1029	3	1	they	PRP	(S(NP*)	-	-	-	-	(11)
ectb_1029	3	2	are	VBP	(VP*	be	03	-	-	-
ectb_1029	3	3	also	RB	(ADVP*)	-	-	-	-	-
ectb_1029	3	4	actively	RB	(ADVP*)	-	-	-	-	-
ectb_1029	3	5	developing	VBG	(VP*	develop	02	-	-	-
ectb_1029	3	6	overseas	JJ	(NP*	-	-	-	-	-
ectb_1029	3	7	markets	NNS	*)))))	market	-	1	-	-
ectb_1029	3	8	,	,	*	-	-	-	-	-
ectb_1029	3	9	what	WP	(S(SBAR(WHNP*)	-	-	-	-	-
ectb_1029	3	10	interests	VBZ	(S(VP*	interest	01	-	-	-
ectb_1029	3	11	them	PRP	(NP*)	-	-	-	-	(11)
ectb_1029	3	12	most	RBS	(ADVP*))))	-	-	-	-	-
ectb_1029	3	13	is	VBZ	(VP*	be	01	2	-	-
ectb_1029	3	14	not	RB	*	-	-	-	-	-
ectb_1029	3	15	biochips	NNS	(NP*)	-	-	-	-	(28)
ectb_1029	3	16	per	FW	(ADVP*	-	-	-	-	-
ectb_1029	3	17	se	FW	*)))	-	-	-	-	-
ectb_1029	3	18	,	,	*	-	-	-	-	-
ectb_1029	3	19	nor	CC	*	-	-	-	-	-
ectb_1029	3	20	are	VBP	(SINV*	be	01	1	-	-
ectb_1029	3	21	they	PRP	(NP*)	-	-	-	-	(11)
ectb_1029	3	22	content	JJ	(ADJP*	-	-	-	-	-
ectb_1029	3	23	merely	RB	(S(ADVP*)	-	-	-	-	-
ectb_1029	3	24	to	TO	(VP*	-	-	-	-	-
ectb_1029	3	25	be	VB	(VP*	be	01	1	-	-
ectb_1029	3	26	contract	NN	(NP*	contract	-	1	-	-
ectb_1029	3	27	manufacturers	NNS	*))))))	manufacturer	-	1	-	-
ectb_1029	3	28	.	.	*))	-	-	-	-	-

ectb_1029	3	0	"	``	(TOP(S*	-	-	-	-	-
ectb_1029	3	1	The	DT	(S(NP*	-	-	-	-	(28
ectb_1029	3	2	chips	NNS	*)	chip	-	11	-	28)
ectb_1029	3	3	are	VBP	(VP*	be	01	1	-	-
ectb_1029	3	4	only	RB	(ADVP*)	-	-	-	-	-
ectb_1029	3	5	a	DT	(NP*	-	-	-	-	-
ectb_1029	3	6	tool	NN	*)))	-	-	-	-	-
ectb_1029	3	7	,	,	*	-	-	-	-	-
ectb_1029	3	8	and	CC	*	-	-	-	-	-
ectb_1029	3	9	the	DT	(S(NP*	-	-	-	-	-
ectb_1029	3	10	big	JJ	*	-	-	-	-	-
ectb_1029	3	11	money	NN	*)	money	-	2	-	-
ectb_1029	3	12	is	VBZ	(VP*	be	01	4	-	-
ectb_1029	3	13	not	RB	*	-	-	-	-	-
ectb_1029	3	14	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	15	chip	NN	(NP*	chip	-	11	-	-
ectb_1029	3	16	sales	NNS	*))))	sale	01	1	-	-
ectb_1029	3	17	.	.	*))	-	-	-	-	-

ectb_1029	3	0	What	WP	(TOP(S(SBAR(WHNP*)	-	-	-	-	-
ectb_1029	3	1	counts	VBZ	(S(VP*)))	count	04	2	-	-
ectb_1029	3	2	is	VBZ	(VP*	be	01	2	-	-
ectb_1029	3	3	the	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	4	R&D	NN	*)	-	-	-	-	-
ectb_1029	3	5	behind	IN	(PP*	-	-	-	-	-
ectb_1029	3	6	them	PRP	(NP*))))	-	-	-	-	(28)
ectb_1029	3	7	.	.	*	-	-	-	-	-
ectb_1029	3	8	"	''	*))	-	-	-	-	-

ectb_1029	3	0	Jerry	NNP	(TOP(S(NP(NP*	-	-	-	-	(22
ectb_1029	3	1	Huang	NNP	*)	-	-	-	-	-
ectb_1029	3	2	,	,	*	-	-	-	-	-
ectb_1029	3	3	executive	JJ	(NP(NP*	-	-	-	-	-
ectb_1029	3	4	vice	NN	*	vice	-	4	-	-
ectb_1029	3	5	president	NN	*)	president	-	1	-	-
ectb_1029	3	6	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	7	U	NNP	(NP(NML*	-	-	-	-	(14
ectb_1029	3	8	-	HYPH	*	-	-	-	-	-
ectb_1029	3	9	Vision	NNP	*)	-	-	-	-	-
ectb_1029	3	10	Biotech	NNP	*))))	-	-	-	-	22)|14)
ectb_1029	3	11	,	,	*	-	-	-	-	-
ectb_1029	3	12	reveals	VBZ	(VP*	reveal	01	2	-	-
ectb_1029	3	13	that	IN	(SBAR*	-	-	-	-	-
ectb_1029	3	14	U	NNP	(S(NP(NP*	-	-	-	-	(14
ectb_1029	3	15	-	HYPH	*	-	-	-	-	-
ectb_1029	3	16	Vision	NNP	*)	-	-	-	-	-
ectb_1029	3	17	,	,	*	-	-	-	-	-
ectb_1029	3	18	which	WDT	(SBAR(WHNP*)	-	-	-	-	-
ectb_1029	3	19	was	VBD	(S(VP*	be	03	-	-	-
ectb_1029	3	20	set	VBN	(VP*	set	03	-	-	-
ectb_1029	3	21	up	RP	(PRT*)	-	-	-	-	-
ectb_1029	3	22	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	23	September	NNP	(NP*	-	-	-	-	-
ectb_1029	3	24	1999	CD	*)))))))	-	-	-	-	14)
ectb_1029	3	25	,	,	*	-	-	-	-	-
ectb_1029	3	26	has	VBZ	(VP*	have	01	-	-	-
ectb_1029	3	27	signed	VBN	(VP*	sign	02	1	-	-
ectb_1029	3	28	a	DT	(NP(NP(NP*	-	-	-	-	-
ectb_1029	3	29	contract	NN	*)	contract	-	1	-	-
ectb_1029	3	30	with	IN	(PP*	-	-	-	-	-
ectb_1029	3	31	the	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	32	US	NNP	*	-	-	-	-	-
ectb_1029	3	33	company	NN	*)	company	-	1	-	-
ectb_1029	3	34	Zen	NNP	(NP*	-	-	-	-	-
ectb_1029	3	35	-	HYPH	*	-	-	-	-	-
ectb_1029	3	36	Bio	NNP	*))))	-	-	-	-	-
ectb_1029	3	37	to	TO	(SBAR(S(VP*	-	-	-	-	-
ectb_1029	3	38	jointly	RB	(ADVP*)	-	-	-	-	-
ectb_1029	3	39	develop	VB	(VP*	develop	02	1	-	-
ectb_1029	3	40	human	NN	(NP*	-	-	-	-	-
ectb_1029	3	41	adipocyte	NN	*	-	-	-	-	-
ectb_1029	3	42	cDNA	NN	*	-	-	-	-	-
ectb_1029	3	43	microarray	NN	*	-	-	-	-	-
ectb_1029	3	44	chips	NNS	*)))))))))))	chip	-	11	-	-
ectb_1029	3	45	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Huang	NNP	(TOP(S(NP*)	-	-	-	-	(22)
ectb_1029	3	1	states	VBZ	(VP*	state	01	1	-	-
ectb_1029	3	2	that	IN	(SBAR*	-	-	-	-	-
ectb_1029	3	3	research	NN	(S(NP(NP*)	research	-	1	-	-
ectb_1029	3	4	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	5	recent	JJ	(NP*	-	-	-	-	-
ectb_1029	3	6	years	NNS	*)))	-	-	-	-	-
ectb_1029	3	7	has	VBZ	(VP*	have	01	-	-	-
ectb_1029	3	8	revealed	VBN	(VP*	reveal	01	2	-	-
ectb_1029	3	9	that	IN	(SBAR*	-	-	-	-	-
ectb_1029	3	10	adipocytes	NNS	(S(NP(NP*)	-	-	-	-	-
ectb_1029	3	11	-LRB-	-LRB-	(NP*	-	-	-	-	-
ectb_1029	3	12	fat	NN	*	-	-	-	-	-
ectb_1029	3	13	cells	NNS	*	cell	-	1	-	-
ectb_1029	3	14	-RRB-	-RRB-	*))	-	-	-	-	-
ectb_1029	3	15	are	VBP	(VP(VP*	be	01	1	-	-
ectb_1029	3	16	active	JJ	(NP(NP*	-	-	-	-	-
ectb_1029	3	17	regulators	NNS	*)	regulator	-	1	-	-
ectb_1029	3	18	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	19	the	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	20	energy	NN	*	energy	-	1	-	-
ectb_1029	3	21	balance	NN	*)	balance	-	1	-	-
ectb_1029	3	22	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	23	the	DT	(NP*	-	-	-	-	-
ectb_1029	3	24	body	NN	*))))))	body	-	2	-	-
ectb_1029	3	25	,	,	*	-	-	-	-	-
ectb_1029	3	26	and	CC	*	-	-	-	-	-
ectb_1029	3	27	play	VBP	(VP*	play	02	3	-	-
ectb_1029	3	28	an	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	29	important	JJ	*	-	-	-	-	-
ectb_1029	3	30	role	NN	*)	role	-	1	-	-
ectb_1029	3	31	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	32	disorders	NNS	(NP(NP*)	disorder	-	1	-	(29
ectb_1029	3	33	such	JJ	(PP*	-	-	-	-	-
ectb_1029	3	34	as	IN	*	-	-	-	-	-
ectb_1029	3	35	obesity	NN	(NP(NP*)	-	-	-	-	-
ectb_1029	3	36	,	,	*	-	-	-	-	-
ectb_1029	3	37	diabetes	NN	(NP*)	-	-	-	-	-
ectb_1029	3	38	,	,	*	-	-	-	-	-
ectb_1029	3	39	osteoporosis	NN	(NP*)	-	-	-	-	-
ectb_1029	3	40	and	CC	*	-	-	-	-	-
ectb_1029	3	41	cardiovascular	JJ	(NP*	-	-	-	-	-
ectb_1029	3	42	disease	NN	*)))))))))))))))	-	-	-	-	29)
ectb_1029	3	43	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Thus	RB	(TOP(S(ADVP*)	-	-	-	-	-
ectb_1029	3	1	it	PRP	(NP(NP*))	-	-	-	-	-
ectb_1029	3	2	is	VBZ	(VP*	be	03	-	-	-
ectb_1029	3	3	hoped	VBN	(VP*	hope	01	1	-	-
ectb_1029	3	4	that	IN	(SBAR*	-	-	-	-	-
ectb_1029	3	5	research	NN	(S(NP(NP*)	research	-	1	-	-
ectb_1029	3	6	into	IN	(PP*	-	-	-	-	-
ectb_1029	3	7	human	NN	(NP*	-	-	-	-	-
ectb_1029	3	8	adipocytes	NNS	*)))	-	-	-	-	-
ectb_1029	3	9	can	MD	(VP*	-	-	-	-	-
ectb_1029	3	10	help	VB	(VP*	help	01	1	-	-
ectb_1029	3	11	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	12	the	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	13	search	NN	*)	search	01	1	-	-
ectb_1029	3	14	for	IN	(PP*	-	-	-	-	-
ectb_1029	3	15	drugs	NNS	(NP(NP(NP*)	-	-	-	-	-
ectb_1029	3	16	and	CC	*	-	-	-	-	-
ectb_1029	3	17	other	JJ	(NP*	-	-	-	-	-
ectb_1029	3	18	therapies	NNS	*))	-	-	-	-	-
ectb_1029	3	19	to	TO	(SBAR(S(VP*	-	-	-	-	-
ectb_1029	3	20	treat	VB	(VP*	treat	03	4	-	-
ectb_1029	3	21	these	DT	(NP*	-	-	-	-	(29
ectb_1029	3	22	disorders	NNS	*)))))))))))))))	disorder	-	1	-	29)
ectb_1029	3	23	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Apart	RB	(TOP(S(ADVP*	-	-	-	-	-
ectb_1029	3	1	from	IN	(PP*	-	-	-	-	-
ectb_1029	3	2	this	DT	(NP*)))	-	-	-	-	-
ectb_1029	3	3	,	,	*	-	-	-	-	-
ectb_1029	3	4	U	NNP	(NP*	-	-	-	-	(14
ectb_1029	3	5	-	HYPH	*	-	-	-	-	-
ectb_1029	3	6	Vision	NNP	*)	-	-	-	-	14)
ectb_1029	3	7	is	VBZ	(VP*	be	03	-	-	-
ectb_1029	3	8	also	RB	(ADVP*)	-	-	-	-	-
ectb_1029	3	9	conducting	VBG	(VP*	conduct	01	2	-	-
ectb_1029	3	10	a	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	11	one	CD	(NML*	-	-	-	-	-
ectb_1029	3	12	-	HYPH	*	-	-	-	-	-
ectb_1029	3	13	year	NN	*)	-	-	-	-	-
ectb_1029	3	14	bacterial	JJ	*	-	-	-	-	-
ectb_1029	3	15	genome	NN	*	-	-	-	-	-
ectb_1029	3	16	project	NN	*)	-	-	-	-	-
ectb_1029	3	17	,	,	*	-	-	-	-	-
ectb_1029	3	18	which	WDT	(SBAR(WHNP*)	-	-	-	-	-
ectb_1029	3	19	aims	VBZ	(S(VP*	aim	01	2	-	-
ectb_1029	3	20	to	TO	(S(VP*	-	-	-	-	-
ectb_1029	3	21	map	VB	(VP*	map	01	3	-	-
ectb_1029	3	22	the	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	23	genome	NN	*)	-	-	-	-	-
ectb_1029	3	24	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	25	a	DT	(NP*	-	-	-	-	-
ectb_1029	3	26	certain	JJ	*	-	-	-	-	-
ectb_1029	3	27	drug	NN	(ADJP*	-	-	-	-	-
ectb_1029	3	28	-	HYPH	*	-	-	-	-	-
ectb_1029	3	29	resistant	JJ	*)	-	-	-	-	-
ectb_1029	3	30	bacterium	NN	*)))	-	-	-	-	-
ectb_1029	3	31	as	IN	(PP*	-	-	-	-	-
ectb_1029	3	32	a	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	33	basis	NN	*)	basis	-	2	-	-
ectb_1029	3	34	for	IN	(PP*	-	-	-	-	-
ectb_1029	3	35	developing	VBG	(S(VP*	develop	02	1	-	-
ectb_1029	3	36	new	JJ	(NP*	-	-	-	-	-
ectb_1029	3	37	vaccines	NNS	*	-	-	-	-	-
ectb_1029	3	38	and	CC	*	-	-	-	-	-
ectb_1029	3	39	drugs	NNS	*)))))))))))))))	-	-	-	-	-
ectb_1029	3	40	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Drug	NN	(TOP(NP*	-	-	-	-	-
ectb_1029	3	1	development	NN	*))	-	-	-	-	-

ectb_1029	3	0	Taiwan	NNP	(TOP(S(NP(NP(NP*	-	-	-	-	(13
ectb_1029	3	1	Genome	NNP	*	-	-	-	-	-
ectb_1029	3	2	Sciences	NNP	*)	-	-	-	-	-
ectb_1029	3	3	-LRB-	-LRB-	(NP*	-	-	-	-	-
ectb_1029	3	4	TGS	NNP	*	-	-	-	-	-
ectb_1029	3	5	-RRB-	-RRB-	*))	-	-	-	-	-
ectb_1029	3	6	,	,	*	-	-	-	-	-
ectb_1029	3	7	which	WDT	(SBAR(WHNP*)	-	-	-	-	-
ectb_1029	3	8	was	VBD	(S(VP*	be	03	-	-	-
ectb_1029	3	9	set	VBN	(VP*	set	03	4	-	-
ectb_1029	3	10	up	RP	(PRT*)	-	-	-	-	-
ectb_1029	3	11	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	12	November	NNP	(NP*	-	-	-	-	-
ectb_1029	3	13	1999	CD	*))	-	-	-	-	-
ectb_1029	3	14	as	IN	(PP*	-	-	-	-	-
ectb_1029	3	15	a	DT	(NP*	-	-	-	-	-
ectb_1029	3	16	joint	JJ	*	-	-	-	-	-
ectb_1029	3	17	venture	NN	*))	venture	-	3	-	-
ectb_1029	3	18	by	IN	(PP*	-	-	-	-	-
ectb_1029	3	19	the	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	20	Uni-President	NNP	*	-	-	-	-	-
ectb_1029	3	21	Enterprises	NNPS	*	-	-	-	-	-
ectb_1029	3	22	Group	NNP	*)	-	-	-	-	-
ectb_1029	3	23	,	,	*	-	-	-	-	-
ectb_1029	3	24	Yuen	NNP	(NP*	-	-	-	-	-
ectb_1029	3	25	Foong	NNP	*	-	-	-	-	-
ectb_1029	3	26	Yu	NNP	*)	-	-	-	-	-
ectb_1029	3	27	and	CC	*	-	-	-	-	-
ectb_1029	3	28	Tuntex	NNP	(NP*	-	-	-	-	-
ectb_1029	3	29	Groups	NNPS	*))))))))	-	-	-	-	13)
ectb_1029	3	30	,	,	*	-	-	-	-	-
ectb_1029	3	31	only	RB	(ADVP*)	-	-	-	-	-
ectb_1029	3	32	entered	VBD	(VP*	enter	01	1	-	-
ectb_1029	3	33	the	DT	(NP*	-	-	-	-	-
ectb_1029	3	34	biotechnology	NN	*	-	-	-	-	-
ectb_1029	3	35	fray	NN	*)	-	-	-	-	-
ectb_1029	3	36	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	37	April	NNP	(NP(NP*)	-	-	-	-	-
ectb_1029	3	38	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	39	this	DT	(NP*	-	-	-	-	-
ectb_1029	3	40	year	NN	*)))))	-	-	-	-	-
ectb_1029	3	41	.	.	*))	-	-	-	-	-

ectb_1029	3	0	CEO	NN	(TOP(S(NP*	-	-	-	-	(2
ectb_1029	3	1	Andrew	NNP	*	-	-	-	-	-
ectb_1029	3	2	Kuo	NNP	*)	-	-	-	-	2)
ectb_1029	3	3	says	VBZ	(VP*	say	01	1	-	-
ectb_1029	3	4	the	DT	(SBAR(S(S(NP*	-	-	-	-	(34
ectb_1029	3	5	investors	NNS	*)	-	-	-	-	34)
ectb_1029	3	6	came	VBD	(VP*	come	01	3	-	-
ectb_1029	3	7	to	IN	(PP*	-	-	-	-	-
ectb_1029	3	8	the	DT	(NP*	-	-	-	-	-
ectb_1029	3	9	view	NN	*	view	-	4	-	-
ectb_1029	3	10	that	IN	(SBAR*	-	-	-	-	-
ectb_1029	3	11	Taiwan	NNP	(S(NP*)	-	-	-	-	(24)
ectb_1029	3	12	needs	VBZ	(VP*	need	01	2	-	-
ectb_1029	3	13	to	TO	(S(VP*	-	-	-	-	-
ectb_1029	3	14	develop	VB	(VP*	develop	02	2	-	-
ectb_1029	3	15	its	PRP$	(NP*	-	-	-	-	(24)
ectb_1029	3	16	biotechnology	NN	*	-	-	-	-	-
ectb_1029	3	17	industries	NNS	*)))))))))))	industry	-	1	-	-
ectb_1029	3	18	,	,	*	-	-	-	-	-
ectb_1029	3	19	and	CC	*	-	-	-	-	-
ectb_1029	3	20	therefore	RB	(S(ADVP*)	-	-	-	-	-
ectb_1029	3	21	they	PRP	(NP*)	-	-	-	-	(34)
ectb_1029	3	22	combined	VBD	(VP*	combine	01	1	-	-
ectb_1029	3	23	their	PRP$	(NP*	-	-	-	-	(34)
ectb_1029	3	24	resources	NNS	*)	resource	-	1	-	-
ectb_1029	3	25	to	TO	(S(VP*	-	-	-	-	-
ectb_1029	3	26	make	VB	(VP*	make	-	1	-	-
ectb_1029	3	27	a	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	28	long	JJ	(NML*	-	-	-	-	-
ectb_1029	3	29	-	HYPH	*	-	-	-	-	-
ectb_1029	3	30	term	NN	*)	-	-	-	-	-
ectb_1029	3	31	investment	NN	*)	investment	01	3	-	-
ectb_1029	3	32	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	33	the	DT	(NP*	-	-	-	-	-
ectb_1029	3	34	field	NN	*)))))))))))	field	-	3	-	-
ectb_1029	3	35	.	.	*))	-	-	-	-	-

ectb_1029	3	0	TGS	NNP	(TOP(S(NP(NP*	-	-	-	-	(13
ectb_1029	3	1	's	POS	*)	-	-	-	-	13)
ectb_1029	3	2	strategy	NN	*)	strategy	-	1	-	-
ectb_1029	3	3	is	VBZ	(VP*	be	01	1	-	-
ectb_1029	3	4	to	TO	(S(VP(VP*	-	-	-	-	-
ectb_1029	3	5	invest	VB	(VP*	invest	01	1	-	-
ectb_1029	3	6	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	7	a	DT	(NP(NP*	-	-	-	-	(20
ectb_1029	3	8	number	NN	*)	number	-	1	-	-
ectb_1029	3	9	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	10	US	NNP	(NP*	-	-	-	-	-
ectb_1029	3	11	genome	NN	*	-	-	-	-	-
ectb_1029	3	12	research	NN	*	-	-	-	-	-
ectb_1029	3	13	companies	NNS	*))))))	company	-	1	-	20)
ectb_1029	3	14	,	,	*	-	-	-	-	-
ectb_1029	3	15	and	CC	*	-	-	-	-	-
ectb_1029	3	16	to	TO	(VP*	-	-	-	-	-
ectb_1029	3	17	sign	VB	(VP*	sign	02	1	-	-
ectb_1029	3	18	technology	NN	(NP(NP(NP*	technology	-	1	-	-
ectb_1029	3	19	transfer	NN	*	-	-	-	-	-
ectb_1029	3	20	agreements	NNS	*)	-	-	-	-	-
ectb_1029	3	21	and	CC	*	-	-	-	-	-
ectb_1029	3	22	chip	NN	(NP*	chip	-	11	-	-
ectb_1029	3	23	production	NN	*	production	-	6	-	-
ectb_1029	3	24	contracts	NNS	*))	contract	-	1	-	-
ectb_1029	3	25	with	IN	(PP*	-	-	-	-	-
ectb_1029	3	26	them	PRP	(NP*))))))))	-	-	-	-	(20)
ectb_1029	3	27	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Kuo	NNP	(TOP(S(S(NP*)	-	-	-	-	(2)
ectb_1029	3	1	comments	VBZ	(VP*	comment	02	1	-	-
ectb_1029	3	2	that	IN	(SBAR*	-	-	-	-	-
ectb_1029	3	3	contract	NN	(S(NP(NP*	contract	-	1	-	-
ectb_1029	3	4	production	NN	*)	production	01	6	-	-
ectb_1029	3	5	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	6	chips	NNS	(NP*)))	chip	-	11	-	-
ectb_1029	3	7	is	VBZ	(VP*	be	01	1	-	-
ectb_1029	3	8	merely	RB	(NP(ADVP*)	-	-	-	-	-
ectb_1029	3	9	a	DT	(NP*	-	-	-	-	-
ectb_1029	3	10	service	NN	*	service	-	1	-	-
ectb_1029	3	11	activity	NN	*)	activity	-	1	-	-
ectb_1029	3	12	and	CC	*	-	-	-	-	-
ectb_1029	3	13	a	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	14	source	NN	*)	source	-	6	-	-
ectb_1029	3	15	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	16	income	NN	(NP(NP*)	-	-	-	-	-
ectb_1029	3	17	for	IN	(PP*	-	-	-	-	-
ectb_1029	3	18	the	DT	(NP*	-	-	-	-	(13
ectb_1029	3	19	company	NN	*)))))))))))	company	-	1	-	13)
ectb_1029	3	20	-	:	*	-	-	-	-	-
ectb_1029	3	21	TGS	NNP	(S(NP(NP*	-	-	-	-	(13
ectb_1029	3	22	's	POS	*)	-	-	-	-	13)
ectb_1029	3	23	ultimate	JJ	*	-	-	-	-	-
ectb_1029	3	24	goal	NN	*)	goal	-	1	-	-
ectb_1029	3	25	is	VBZ	(VP*	be	01	1	-	-
ectb_1029	3	26	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	27	doing	VBG	(S(VP*	do	-	1	-	-
ectb_1029	3	28	R&D	NN	(NP*	-	-	-	-	-
ectb_1029	3	29	work	NN	*)	work	01	1	-	-
ectb_1029	3	30	to	TO	(S(VP*	-	-	-	-	-
ectb_1029	3	31	identify	VB	(VP*	identify	01	1	-	-
ectb_1029	3	32	gene	NN	(NP(NP*	-	-	-	-	-
ectb_1029	3	33	sequences	NNS	*)	-	-	-	-	-
ectb_1029	3	34	as	IN	(PP*	-	-	-	-	-
ectb_1029	3	35	targets	NNS	(NP(NP*)	target	-	1	-	-
ectb_1029	3	36	for	IN	(PP*	-	-	-	-	-
ectb_1029	3	37	developing	VBG	(S(VP*	develop	02	1	-	-
ectb_1029	3	38	new	JJ	(NP*	-	-	-	-	-
ectb_1029	3	39	drugs	NNS	*)))))))))))))))	-	-	-	-	-
ectb_1029	3	40	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Kuo	NNP	(TOP(S(NP*)	-	-	-	-	(2)
ectb_1029	3	1	states	VBZ	(VP*	state	01	1	-	-
ectb_1029	3	2	that	IN	(SBAR*	-	-	-	-	-
ectb_1029	3	3	at	IN	(S(S(PP*	-	-	-	-	-
ectb_1029	3	4	present	NN	(NP*))	present	-	1	-	-
ectb_1029	3	5	,	,	*	-	-	-	-	-
ectb_1029	3	6	the	DT	(NP(NP*	-	-	-	-	-
ectb_1029	3	7	number	NN	*)	number	-	1	-	-
ectb_1029	3	8	of	IN	(PP*	-	-	-	-	-
ectb_1029	3	9	known	JJ	(NP(NP*	-	-	-	-	-
ectb_1029	3	10	target	NN	*	target	-	1	-	-
ectb_1029	3	11	sequences	NNS	*)	-	-	-	-	-
ectb_1029	3	12	for	IN	(PP*	-	-	-	-	-
ectb_1029	3	13	disease	NN	(NP(ADJP*	-	-	-	-	-
ectb_1029	3	14	-	HYPH	*	-	-	-	-	-
ectb_1029	3	15	treating	VBG	*)	treat	03	-	-	-
ectb_1029	3	16	drugs	NNS	*)))))	-	-	-	-	-
ectb_1029	3	17	is	VBZ	(VP*	be	01	1	-	-
ectb_1029	3	18	only	RB	(NP(QP*	-	-	-	-	-
ectb_1029	3	19	around	RB	*	-	-	-	-	-
ectb_1029	3	20	500	CD	*))))	-	-	-	-	-
ectb_1029	3	21	,	,	*	-	-	-	-	-
ectb_1029	3	22	but	CC	*	-	-	-	-	-
ectb_1029	3	23	as	IN	(S(SBAR*	-	-	-	-	-
ectb_1029	3	24	the	DT	(S(NP*	-	-	-	-	-
ectb_1029	3	25	human	NN	*	-	-	-	-	-
ectb_1029	3	26	genome	NN	*)	-	-	-	-	-
ectb_1029	3	27	is	VBZ	(VP*	be	03	-	-	-
ectb_1029	3	28	mapped	VBN	(VP*	map	01	-	-	-
ectb_1029	3	29	out	RP	(PRT*)))))	-	-	-	-	-
ectb_1029	3	30	this	DT	(NP*	-	-	-	-	-
ectb_1029	3	31	number	NN	*)	number	-	2	-	-
ectb_1029	3	32	can	MD	(VP*	-	-	-	-	-
ectb_1029	3	33	be	VB	(VP*	be	03	-	-	-
ectb_1029	3	34	expected	VBN	(VP*	expect	01	-	-	-
ectb_1029	3	35	to	TO	(S(VP*	-	-	-	-	-
ectb_1029	3	36	increase	VB	(VP*	increase	01	1	-	-
ectb_1029	3	37	tenfold	RB	(ADVP*)))))))))))	-	-	-	-	-
ectb_1029	3	38	.	.	*))	-	-	-	-	-

ectb_1029	3	0	Currently	RB	(TOP(S(ADVP*)	-	-	-	-	-
ectb_1029	3	1	,	,	*	-	-	-	-	-
ectb_1029	3	2	TGS	NNP	(NP*)	-	-	-	-	(13)
ectb_1029	3	3	has	VBZ	(VP*	have	03	12	-	-
ectb_1029	3	4	its	PRP$	(NP(NP*	-	-	-	-	(13)
ectb_1029	3	5	sights	NNS	*)	-	-	-	-	-
ectb_1029	3	6	set	VBN	(VP*	set	01	-	-	-
ectb_1029	3	7	mainly	RB	(PP(ADVP*)	-	-	-	-	-
ectb_1029	3	8	on	IN	*	-	-	-	-	-
ectb_1029	3	9	doing	VBG	(S(VP*	do	-	1	-	-
ectb_1029	3	10	research	NN	(NP(NP*)	research	-	1	-	-
ectb_1029	3	11	into	IN	(PP*	-	-	-	-	-
ectb_1029	3	12	diseases	NNS	(NP(NP(NP*)	-	-	-	-	-
ectb_1029	3	13	which	WDT	(SBAR(WHNP*)	-	-	-	-	-
ectb_1029	3	14	are	VBP	(S(VP*	be	01	1	-	-
ectb_1029	3	15	especially	RB	(ADJP*	-	-	-	-	-
ectb_1029	3	16	prevalent	JJ	*)	-	-	-	-	-
ectb_1029	3	17	in	IN	(PP*	-	-	-	-	-
ectb_1029	3	18	Asia	NNP	(NP*))))))	-	-	-	-	-
ectb_1029	3	19	,	,	*	-	-	-	-	-
ectb_1029	3	20	such	JJ	(PP*	-	-	-	-	-
ectb_1029	3	21	as	IN	*	-	-	-	-	-
ectb_1029	3	22	liver	NN	(NP(NML*	-	-	-	-	-
ectb_1029	3	23	and	CC	*	-	-	-	-	-
ectb_1029	3	24	stomach	NN	*)	-	-	-	-	-
ectb_1029	3	25	cancers	NNS	*)))))))))))	cancer	-	1	-	-
ectb_1029	3	26	.	.	*))	-	-	-	-	-

#end document
